EA200401014A1 - Фармацевтические композиции, содержащие один или несколько стероидов, один или несколько тетрагидрофолатных компонентов и витамин в - Google Patents

Фармацевтические композиции, содержащие один или несколько стероидов, один или несколько тетрагидрофолатных компонентов и витамин в

Info

Publication number
EA200401014A1
EA200401014A1 EA200401014A EA200401014A EA200401014A1 EA 200401014 A1 EA200401014 A1 EA 200401014A1 EA 200401014 A EA200401014 A EA 200401014A EA 200401014 A EA200401014 A EA 200401014A EA 200401014 A1 EA200401014 A1 EA 200401014A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tetrahydrofolate
several
acid
vitamin
steroids
Prior art date
Application number
EA200401014A
Other languages
English (en)
Other versions
EA007599B1 (ru
Inventor
Герман Ян Теймен Кулинг Беннинк
Original Assignee
Шеринг Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шеринг Акциенгезельшафт filed Critical Шеринг Акциенгезельшафт
Publication of EA200401014A1 publication Critical patent/EA200401014A1/ru
Publication of EA007599B1 publication Critical patent/EA007599B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • A61K31/714Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

В заявке описан набор для применения в способе гормональной контрацепции или гормонзаместительной терапии особей млекопитающих женского пола, который включает по меньшей мере 10 оральных стандартных доз, содержащих по меньшей мере 1 мкг одного или нескольких стероидов, выбранных из ряда, включающего эстрогены и прогестогены; по меньшей мере 0,1 мг одного или нескольких тетрагидрофолатных компонентов, выбранных из ряда, включающего (6S)-тетрагидрофолиевую кислоту, 5-метил-(6S)-тетрагидрофолиевую кислоту, 5-формил-(6S)-тетрагидрофолиевую кислоту, 10-формил-(6S)-тетрагидрофолиевую кислоту, 5,10-метилен-(6R)-тетрагидрофолиевую кислоту, 5,10-метенил-(6R)-тетрагидрофолиевую кислоту, 5-формимино-(6S)-тетрагидрофолиевую кислоту, фармацевтически приемлемые соли указанных тетрафолиевых кислот и глутамильные производные указанных тетрагидрофолиевых кислот; и по меньшей мере 0,1 мг витамина B. В заявке описаны также способ гормональной контрацепции и способ гормонзаместительной терапии, заключающиеся в том, что особи млекопитающего женского пола вводят орально по меньшей мере один раз в день одну или несколько содержащих стероиды стандартных доз, где стандартные дозы дополнительно содержат по меньшей мере 0,1 мг одного или нескольких указанных выше тетрагидрофолатных компонентов и по меньшей мере 0,1 мг витамина B.
EA200401014A 2002-02-21 2002-11-15 Фармацевтические композиции, содержащие один или несколько стероидов, один или несколько тетрагидрофолатных компонентов и витамин в EA007599B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02075695 2002-02-21
PCT/NL2002/000741 WO2003070255A1 (en) 2002-02-21 2002-11-15 Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin b12

Publications (2)

Publication Number Publication Date
EA200401014A1 true EA200401014A1 (ru) 2006-10-27
EA007599B1 EA007599B1 (ru) 2006-12-29

Family

ID=27741182

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401014A EA007599B1 (ru) 2002-02-21 2002-11-15 Фармацевтические композиции, содержащие один или несколько стероидов, один или несколько тетрагидрофолатных компонентов и витамин в

Country Status (29)

Country Link
US (1) US20050164977A1 (ru)
EP (1) EP1478373B1 (ru)
JP (1) JP5037779B2 (ru)
KR (1) KR100936827B1 (ru)
CN (1) CN1620302B (ru)
AT (1) ATE341333T1 (ru)
AU (1) AU2002343249B2 (ru)
BR (1) BR0215613A (ru)
CA (1) CA2476940C (ru)
CR (1) CR7420A (ru)
CY (1) CY1106273T1 (ru)
DE (1) DE60215224T2 (ru)
DK (1) DK1478373T3 (ru)
EA (1) EA007599B1 (ru)
EC (1) ECSP045305A (ru)
ES (1) ES2274107T3 (ru)
HK (1) HK1078780A1 (ru)
HU (1) HUP0402674A3 (ru)
IL (2) IL163579A0 (ru)
ME (1) MEP37208A (ru)
MX (1) MXPA04008185A (ru)
NO (1) NO20043932L (ru)
NZ (1) NZ534806A (ru)
PL (1) PL209558B1 (ru)
PT (1) PT1478373E (ru)
RS (1) RS50909B (ru)
UA (1) UA80965C2 (ru)
WO (1) WO2003070255A1 (ru)
ZA (1) ZA200407545B (ru)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005023301B4 (de) * 2005-05-13 2012-05-31 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat
US20060293295A1 (en) * 2005-05-13 2006-12-28 Kai Strothmann Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl- (6S)-tetrahydrofolate
UY29527A1 (es) * 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
AU2012227235B2 (en) * 2005-05-13 2015-06-11 Bayer Intellectual Property Gmbh Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6S)-tetrahydrofolate
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
JP2009542588A (ja) * 2006-07-06 2009-12-03 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 避妊及び先天的異常の危険性の予防のための医薬製剤
AU2013202756B2 (en) * 2006-07-06 2015-06-04 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
EP1891959A1 (de) * 2006-08-14 2008-02-27 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
GB0715502D0 (en) * 2007-08-08 2007-09-19 Univ Manchester Methods
MX2010008940A (es) * 2008-02-13 2010-10-05 Bayer Schering Pharma Ag Sistemas de administracion de drogas que contienen estradiol.
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
PL2324832T5 (pl) * 2009-11-09 2017-10-31 Biogena Naturprodukte Gmbh & Co Kg Suplement diety przy przyjmowaniu hormonalnych środków antykoncepcyjnych
PL2714710T3 (pl) 2011-06-01 2017-03-31 Estetra S.P.R.L. Sposób wytwarzania estetrolowych związków pośrednich
KR101957937B1 (ko) 2011-06-01 2019-03-14 에스테트라 에스.피.알.엘. 에스테트롤 중간체의 제조 방법
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
ES2925534T3 (es) * 2011-11-05 2022-10-18 South Alabama Medical Science Found Métodos, formulaciones y kits para reponer rápidamente los niveles de folato en mujeres
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HRP20211377T1 (hr) 2011-11-23 2022-01-07 Therapeuticsmd, Inc. Prirodne kombinirane hormonske supstitucijske formulacije i terapije
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP6447931B2 (ja) * 2013-12-12 2019-01-09 ドネスタ バイオサイエンス ビー.ブイ.Donesta Bioscience B.V. エステトロール成分を含有する口腔内崩壊固体単位剤形
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JP6866561B2 (ja) 2015-06-18 2021-04-28 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロールを含有する口腔内崩壊錠
RS62844B1 (sr) 2015-06-18 2022-02-28 Estetra Srl Orodisperzibilna dozna jedinica koja sadrži komponentu estetrola
CA2988498C (en) 2015-06-18 2022-02-08 Mithra Pharmaceuticals S.A. Orodispersible dosage unit containing an estetrol component
SI3310346T1 (sl) 2015-06-18 2021-07-30 Estetra Sprl Orodisperzibilna tableta, ki vsebuje estetrol
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. ステロイドホルモン薬学的組成物
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU722050B2 (en) * 1996-01-31 2000-07-20 South Alabama Medical Science Foundation Food and vitamin preparations containing the natural isomer of reduced folates
EP0934060A4 (en) * 1996-07-30 2001-01-03 Energetics FOOD SUPPLEMENTS
US6274564B1 (en) * 1996-09-18 2001-08-14 William J. Sarill Compositions of cobalamin and related corrinoids, and uses thereof
US6220453B1 (en) * 1998-04-07 2001-04-24 Fuji Photo Film Co., Ltd. Blood filter unit
CA2522761C (en) * 1998-04-17 2010-07-06 Michael E. Kafrissen Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
WO1999065337A1 (en) * 1998-06-19 1999-12-23 Beth Israel Deaconess Medical Center Dietary supplement for post-menopausal women
US6479545B1 (en) * 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
DE10022510A1 (de) * 2000-05-10 2001-11-15 Basf Ag Zusammensetzungen enthaltend Folsäure und reduziertes Folat
BG104880A (en) * 2000-10-24 2002-04-30 Иван ХРИСТОВ Medicamentous preparation for multiple sclerosis treatment

Also Published As

Publication number Publication date
HUP0402674A3 (en) 2012-12-28
HUP0402674A2 (hu) 2005-04-28
CN1620302B (zh) 2011-04-27
CN1620302A (zh) 2005-05-25
DK1478373T3 (da) 2007-01-15
JP5037779B2 (ja) 2012-10-03
IL163579A (en) 2011-03-31
ES2274107T3 (es) 2007-05-16
KR100936827B1 (ko) 2010-01-14
IL163579A0 (en) 2005-12-18
CA2476940A1 (en) 2003-08-28
DE60215224T2 (de) 2007-08-23
PL209558B1 (pl) 2011-09-30
RS50909B (sr) 2010-08-31
JP2005523283A (ja) 2005-08-04
NO20043932L (no) 2004-11-19
UA80965C2 (en) 2007-11-26
ECSP045305A (es) 2004-10-26
DE60215224D1 (de) 2006-11-16
EP1478373A1 (en) 2004-11-24
WO2003070255A1 (en) 2003-08-28
HK1078780A1 (en) 2006-03-24
ZA200407545B (en) 2006-06-28
US20050164977A1 (en) 2005-07-28
BR0215613A (pt) 2004-12-07
PL371441A1 (en) 2005-06-13
NZ534806A (en) 2006-05-26
KR20040094711A (ko) 2004-11-10
CA2476940C (en) 2011-11-01
EP1478373B1 (en) 2006-10-04
AU2002343249A1 (en) 2003-09-09
AU2002343249B2 (en) 2009-02-05
RS73304A (en) 2007-02-05
ATE341333T1 (de) 2006-10-15
CY1106273T1 (el) 2011-10-12
CR7420A (es) 2006-02-06
EA007599B1 (ru) 2006-12-29
PT1478373E (pt) 2007-01-31
MEP37208A (en) 2011-02-10
MXPA04008185A (es) 2004-11-26

Similar Documents

Publication Publication Date Title
EA200401014A1 (ru) Фармацевтические композиции, содержащие один или несколько стероидов, один или несколько тетрагидрофолатных компонентов и витамин в
AU739544B2 (en) The use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation suitable for the influencing the homocysteine level, particularly for assisting the remethylation of homocysteine
RU98111617A (ru) Применение тетрагидрофолатов естественной стереоизомерной формы при получении фармацевтической композиции, предназначенной для воздействия на уровень гомоцистеина, в частности для поддержания процесса реметилирования гомоцистеина
WO2006099233B1 (en) Compositions and methods for the treatment of osteoporosis and inflammatory joint disease
WO2004066910A8 (en) Controlled release modifying complex and pharmaceutical compositions thereof
WO1999053910A2 (en) Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
AU2766689A (en) New pharmaceutical formulations with programmed release
US20080268048A1 (en) Pharmaceutical composition for contraception and for reducing the risk of congenital abnormalities
PL1635792T3 (pl) Stabilne kompozycje farmaceutyczne pochodnych kwasu 2-aza-bicyklo[3.3.0]-oktano-3-karboksylowego
WO2005092441A3 (en) Extended cycle multiphasic oral contraceptive method
US20050113332A1 (en) Compositions and methods for treating an arthritic condition
EP0653209A4 (en) MEDICINAL PRODUCTS FOR INFLAMMATORY COLON DISEASES.
EP1891959A1 (de) Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
CA2295389A1 (en) Method of treatment of nausea, vomiting, and other disorders using estrogens
TH105386A (th) องค์ประกอบทางเภสัชกรรมซึ่งประกอบรวมด้วยโปรเจสโตเจน และ/หรือ เอสโตรเจน และ 5-เมธิล-(6s)-เททระไฮโดรโฟเลต
MXPA98004683A (en) The use of tetrahydrofolates in a natural stereoisomeric form for the production of an adequate pharmaceutical preparation to influence the homocysteine level, particularly to help in the homociste remedy

Legal Events

Date Code Title Description
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU